Please replace all prior claims in the application with the following:

Claim 1 (currently amended): A liquid pharmaceutical composition comprising:

an amino acid selected from the group consisting of gabapentin and pregabalin;

one or more polyhydric alcohols, each containing 2 to 6 carbon atoms; and

water;

wherein the one or more polyhydric alcohols comprises about 25 g to about 75 g per 100 mL of the composition and the composition has a pH of about ~~5.5~~ 6.5 to about 7.0.

Claim 2 (previously presented): The composition according to claim 1, wherein the one or more polyhydric alcohols each contains 3 to 5 carbon atoms.

Claim 3 (previously presented): The composition according to claim 1, wherein the one or more polyhydric alcohols are selected from the group consisting of: glycerol, xylitol, sorbitol, mannitol, and mixtures thereof, and wherein the one or more polyhydric alcohols comprises about 40 g to about 75 g per 100 mL of the composition.

Claim 4 (canceled)

Claim 5 (previously presented): The composition according to claim 1, comprising one or both of: a preservative and a flavor improver, wherein the flavor improver does not contain an aldehyde or keto functionality.

Claims 6-11 (canceled)

Claim 12 (currently amended): The composition according to claim 1 ~~or claim 9~~ wherein the amino acid is gabapentin.

Claim 13 (currently amended): The composition according to claim 1 ~~or claim 9~~ wherein the composition has less than 0.5% by weight of the corresponding lactam of the amino acid.

Claim 14 (currently amended): The composition of claim 1, wherein the amino acid is gabapentin, and the composition contains less than 0.5% weight/weight of gabapentin lactam after storage at 2°C to 10°C for 18 months to 2 years~~, wherein the one or more polyhydric alcohols comprises at least 25 g per 100 mL of the composition~~.

Claims 15-17 (canceled)

Claim 18 (currently amended): The composition of claim 1, wherein the amino acid is gabapentin, the one or more polyhydric alcohols is selected from the group consisting of xylitol, glycerol and mixtures thereof~~ and comprises about 25 g to about 75 g per 100 mL of the composition, and the composition has a pH of about 5.5 to about 7.0~~.

Claim 19 (withdrawn): A method of treating a subject suffering from a cerebral disease, including epilepsy, faintness attacks, or hypokinesia; cranial trauma; a neurodegenerative disorder; depression; mania; bipolar disorder; anxiety; panic; inflammation; renal colic; insomnia; gastrointestinal damage; incontinence; migraine; or pain, including neuropathic pain, muscular pain, or skeletal pain, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition according to claim 1[[,]] or claim ~~14 or claim 18~~.